PedAM
Pediatric Disease Annotations & Medicines
| Disease | multiple sclerosis |
| Phenotype | C0270612|leukoencephalopathy |
| Sentences | 20 |
| PubMedID- 24242357 | Objective: to identify cases of laboratory- or biopsy-confirmed progressive multifocal leukoencephalopathy (pml) in patients with multiple sclerosis (ms) who previously discontinued natalizumab (ntz) for reasons unrelated to suspected or proven pml and assess pml risk factors in these cases. |
| PubMedID- 23493158 | Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. |
| PubMedID- 20298967 | Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. |
| PubMedID- 20442571 | Recent findings: natalizumab, a mab targeting the alpha-4 integrins, which is efficient in relapsing-remitting multiple sclerosis, has been associated with progressive multifocal leukoencephalopathy (pml). |
| PubMedID- 24852919 | Blood mirna expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. |
| PubMedID- 24136456 | Progressive multifocal leukoencephalopathy in multiple sclerosis. |
| PubMedID- 21576685 | Objective: natalizumab, a therapy for multiple sclerosis (ms), has been associated with progressive multifocal leukoencephalopathy (pml), a rare opportunistic infection of the cns associated with the jc virus. |
| PubMedID- 25908254 | Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis. |
| PubMedID- 25205744 | Objective: to investigate the mri manifestation pattern of asymptomatic natalizumab-associated progressive multifocal leukoencephalopathy (pml) in patients with multiple sclerosis (ms). |
| PubMedID- 23555065 | Early magnetic resonance detection of natalizumab-related progressive multifocal leukoencephalopathy in a patient with multiple sclerosis. |
| PubMedID- 25698174 | Objective: the objective of this paper is to estimate the risk of reaching well-established disability milestones after withdrawal of natalizumab (ntz) due to concern about the risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis (ms). |
| PubMedID- 24664166 | Importance: infection with jc virus (jcv) may lead to development of demyelinating progressive multifocal leukoencephalopathy in patients with multiple sclerosis (ms) who are treated with natalizumab. |
| PubMedID- 24614671 | Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis. |
| PubMedID- 26394704 | Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. |
| PubMedID- 23323645 | Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy. |
| PubMedID- 22585288 | Natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis (ms) occurred in two individuals also treated with interferon beta1a, raising concerns about the interaction of these disease-modifying agents and leading to the recommendation to avoid their concomitant administration. |
| PubMedID- 23338729 | Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. |
| PubMedID- 22054236 | Background and purpose: temporary discontinuation of natalizumab is sometimes considered as the observed risk of progressive multifocal leukoencephalopathy (pml) in patients with multiple sclerosis (ms). |
| PubMedID- 26190565 | Due to an association of the anti-integrin agent natalizumab with progressive multifocal leukoencephalopathy (pml) in patients with multiple sclerosis (ms), a newly developed anti-jcv antibody assay has been implemented as a risk-stratification tool for natalizumab-treated patients with ms. |
| PubMedID- 24128680 | Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study. |
Page: 1